<DOC>
	<DOCNO>NCT00746382</DOCNO>
	<brief_summary>The aim proof concept study show safety efficacy 0.5 % dermal roflumilast cream treatment atopic dermatitis adult . This multicenter , randomize , double-blind , placebo-controlled , parallel group study . 2-5 % body surface area ( BSA ) cover mild form atopic dermatitis . In 4-week treatment period 38 mg cream apply two time daily 0.5 1 % BSA . After screen phase , washout phase flexible duration ( max 30 day , time depend upon pre-medication ) , 28 day treatment phase follows.As roflumilast potent antiinflammatory substance , positive effect form dermal disease anticipate .</brief_summary>
	<brief_title>A Placebo Controlled 4 Week Proof Concept Study With 0.5 % Roflumilast Cream Patients With Mild Atopic Dermatitis ( RO-2351-001-EM )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Patient /who able read , write fully understand English language ) inform verbally write objective clinical study , method , anticipate benefit potential risk discomfort he/she may expose , give write consent participation study prior study start studyrelated procedure . Patients suffer mild , stable atopic dermatitis Male female patient ethnic origin , age 18 year old present minimum 2 % maximum 5 % BSA affect stable mild atopic dermatitis ( IgE &gt; 10 ) proven dermatologist . Patients must least one target lesion least 0.5 % BSA . No evidence ooze crust atopic dermatitis No lichenification diseased lesion No excoriation diseased lesion Patients must willing wash current active therapy least 14 day Day 1 . Women childbearing potential must negative pregnancy test Screening Baseline Visits agree use highly effective method birth control . A highly effective birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectable , combined oral contraceptive , IUDs , sexual abstinence vasectomise partner . Patient spontaneously improve rapidly deteriorate atopic dermatitis . Patient physical condition , Investigator´s opinion , might impair evaluation atopic dermatitis expose patient unacceptable risk study participation . Patient prolong exposure natural artificial source ultraviolet radiation within 30 day prior initiation treatment intend exposure study think Investigator likely modify patient´s disease . The patient topical transdermal treatment , limited retinoids , nicotine hormone replacement therapy , near intend site application within 14 day prior first application study medication . Use topical preparation contain vitamin , supplement herbal within 14 day prior application . Treatment systemic/locally act medications/procedures might counter influence study aim within 30 day start study /e.g . antihistamine , topical glucocorticosteroids , pimecrolimus , tacrolimus systematic desensitization ) Patient pregnant , nurse plan pregnancy study period . Patient receive investigational drug investigational device within 30 day prior study start . Abuse alcohol drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mild atopic dermatitis , Roflumilast cream 0.5 %</keyword>
</DOC>